Soft Tissue Sarcoma - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 386 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Soft Tissue Sarcoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Soft Tissue Sarcoma - Pipeline Review, H1 2015', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Soft Tissue Sarcoma - Overview 11
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12
Soft Tissue Sarcoma - Therapeutics under Development by Companies 13
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 18
Soft Tissue Sarcoma - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Soft Tissue Sarcoma - Products under Development by Companies 23
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 28
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 29
A. Menarini Industrie Farmaceutiche Riunite Srl 29
Advanced Proteome Therapeutics Corporation 30
Advenchen Laboratories, LLC 31
Altor BioScience Corporation 32
Amgen Inc. 33
Bayer AG 34
Bellicum Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
CASI Pharmaceuticals Inc. 37
Celgene Corporation 38
Cellectar Biosciences, Inc. 39
CytRx Corporation 40
Daiichi Sankyo Company, Limited 41
Eisai Co., Ltd. 42
Eli Lilly and Company 43
EpiZyme, Inc. 44
Exelixis, Inc. 45
Gem Pharmaceuticals, LLC 46
Immune Design Corp. 47
Karyopharm Therapeutics, Inc. 48
Loxo Oncology, Inc. 49
MedImmune, LLC 50
Merck & Co., Inc. 51
Merrimack Pharmaceuticals, Inc. 52
Mirati Therapeutics Inc. 53
MolMed S.p.A. 54
Morphotek, Inc. 55
Nanobiotix 56
Neotropix, Inc. 57
Novartis AG 58
Oncos Therapeutics Ltd. 59
Onxeo SA 60
Pfizer Inc. 61
Pharma Mar, S.A. 62
Plexxikon Inc. 63
Polaris Pharmaceuticals, Inc. 64
Recombio S.L 65
Rigontec GmbH 66
Sanofi 67
Shionogi & Co., Ltd. 68
Siena Biotech S.p.A. 69
Sigma-Tau S.p.A. 70
Sumitomo Dainippon Pharma Co., Ltd. 71
Threshold Pharmaceuticals, Inc. 72
TRACON Pharmaceuticals, Inc. 73
Vicore Pharma AB 74
Soft Tissue Sarcoma - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 82
Assessment by Route of Administration 86
Assessment by Molecule Type 88
Drug Profiles 90
afatinib - Drug Profile 90
AL-3818 - Drug Profile 94
aldoxorubicin hydrochloride - Drug Profile 96
ALT-836 - Drug Profile 99
APC-103 - Drug Profile 101
belinostat - Drug Profile 102
BI-853520 - Drug Profile 105
C-21 - Drug Profile 106
cabazitaxel - Drug Profile 108
cabozantinib s-malate - Drug Profile 110
cancer vaccine - Drug Profile 113
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 114
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 115
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 116
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 117
celyvir - Drug Profile 118
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 120
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 121
DSR-6434 - Drug Profile 122
durvalumab + tremelimumab - Drug Profile 123
E-6438 - Drug Profile 125
efatutazone - Drug Profile 127
ENMD-2076 - Drug Profile 129
eribulin mesylate - Drug Profile 131
everolimus - Drug Profile 135
evofosfamide - Drug Profile 140
G-100 - Drug Profile 148
ganitumab - Drug Profile 149
GPX-150 - Drug Profile 152
I131-CLR1404 - Drug Profile 155
ImOl-100 - Drug Profile 157
irinotecan sucrosofate liposomal - Drug Profile 158
KRA-0008 - Drug Profile 161
LK-3 - Drug Profile 162
LOXO-101 - Drug Profile 163
mocetinostat - Drug Profile 165
MVXONCO-1 - Drug Profile 168
NBTX-TOPO - Drug Profile 169
NBTXR-3 - Drug Profile 170
NGR-hTNF - Drug Profile 172
NOV-110501 - Drug Profile 176
NTX-010 - Drug Profile 177
olaratumab - Drug Profile 179
ONCOS-102 - Drug Profile 181
ontuxizumab - Drug Profile 182
paclitaxel albumin bound - Drug Profile 184
palbociclib - Drug Profile 187
panobinostat - Drug Profile 191
pazopanib hydrochloride - Drug Profile 197
pembrolizumab - Drug Profile 202
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 209
PLX-7486 - Drug Profile 211
regorafenib - Drug Profile 212
ribociclib - Drug Profile 215
S-588410 - Drug Profile 218
sabarubicin - Drug Profile 219
selinexor - Drug Profile 221
SEN-461 - Drug Profile 226
SST-0001 - Drug Profile 227
talimogene laherparepvec - Drug Profile 228
TNF-PEG 20 - Drug Profile 231
trabectedin - Drug Profile 232
TRC-105 - Drug Profile 236
vorinostat - Drug Profile 239
Soft Tissue Sarcoma - Recent Pipeline Updates 243
Soft Tissue Sarcoma - Dormant Projects 366
Soft Tissue Sarcoma - Discontinued Products 371
Soft Tissue Sarcoma - Product Development Milestones 372
Featured News & Press Releases 372
Appendix 381
Methodology 381
Coverage 381
Secondary Research 381
Primary Research 381
Expert Panel Validation 381
Contact Us 381
Disclaimer 382

List of Tables

Number of Products under Development for Soft Tissue Sarcoma, H1 2015 15
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Products under Development by Companies, H1 2015 27
Products under Development by Companies, H1 2015 (Contd..1) 28
Products under Development by Companies, H1 2015 (Contd..2) 29
Products under Development by Companies, H1 2015 (Contd..3) 30
Products under Development by Companies, H1 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 33
Soft Tissue Sarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 34
Soft Tissue Sarcoma - Pipeline by Advenchen Laboratories, LLC, H1 2015 35
Soft Tissue Sarcoma - Pipeline by Altor BioScience Corporation, H1 2015 36
Soft Tissue Sarcoma - Pipeline by Amgen Inc., H1 2015 37
Soft Tissue Sarcoma - Pipeline by Bayer AG, H1 2015 38
Soft Tissue Sarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 39
Soft Tissue Sarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 40
Soft Tissue Sarcoma - Pipeline by CASI Pharmaceuticals Inc., H1 2015 41
Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H1 2015 42
Soft Tissue Sarcoma - Pipeline by Cellectar Biosciences, Inc., H1 2015 43
Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H1 2015 44
Soft Tissue Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 45
Soft Tissue Sarcoma - Pipeline by Eisai Co., Ltd., H1 2015 46
Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H1 2015 47
Soft Tissue Sarcoma - Pipeline by EpiZyme, Inc., H1 2015 48
Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H1 2015 49
Soft Tissue Sarcoma - Pipeline by Gem Pharmaceuticals, LLC, H1 2015 50
Soft Tissue Sarcoma - Pipeline by Immune Design Corp., H1 2015 51
Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 52
Soft Tissue Sarcoma - Pipeline by Loxo Oncology, Inc., H1 2015 53
Soft Tissue Sarcoma - Pipeline by MedImmune, LLC, H1 2015 54
Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H1 2015 55
Soft Tissue Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 56
Soft Tissue Sarcoma - Pipeline by Mirati Therapeutics Inc., H1 2015 57
Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H1 2015 58
Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H1 2015 59
Soft Tissue Sarcoma - Pipeline by Nanobiotix, H1 2015 60
Soft Tissue Sarcoma - Pipeline by Neotropix, Inc., H1 2015 61
Soft Tissue Sarcoma - Pipeline by Novartis AG, H1 2015 62
Soft Tissue Sarcoma - Pipeline by Oncos Therapeutics Ltd., H1 2015 63
Soft Tissue Sarcoma - Pipeline by Onxeo SA, H1 2015 64
Soft Tissue Sarcoma - Pipeline by Pfizer Inc., H1 2015 65
Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H1 2015 66
Soft Tissue Sarcoma - Pipeline by Plexxikon Inc., H1 2015 67
Soft Tissue Sarcoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 68
Soft Tissue Sarcoma - Pipeline by Recombio S.L, H1 2015 69
Soft Tissue Sarcoma - Pipeline by Rigontec GmbH, H1 2015 70
Soft Tissue Sarcoma - Pipeline by Sanofi, H1 2015 71
Soft Tissue Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2015 72
Soft Tissue Sarcoma - Pipeline by Siena Biotech S.p.A., H1 2015 73
Soft Tissue Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2015 74
Soft Tissue Sarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 75
Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 76
Soft Tissue Sarcoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 77
Soft Tissue Sarcoma - Pipeline by Vicore Pharma AB, H1 2015 78
Assessment by Monotherapy Products, H1 2015 79
Assessment by Combination Products, H1 2015 80
Number of Products by Stage and Target, H1 2015 82
Number of Products by Stage and Mechanism of Action, H1 2015 87
Number of Products by Stage and Route of Administration, H1 2015 91
Number of Products by Stage and Molecule Type, H1 2015 93
Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H1 2015 247
Soft Tissue Sarcoma - Dormant Projects, H1 2015 370
Soft Tissue Sarcoma - Dormant Projects (Contd..1), H1 2015 371
Soft Tissue Sarcoma - Dormant Projects (Contd..2), H1 2015 372
Soft Tissue Sarcoma - Dormant Projects (Contd..3), H1 2015 373
Soft Tissue Sarcoma - Dormant Projects (Contd..4), H1 2015 374
Soft Tissue Sarcoma - Discontinued Products, H1 2015 375